563 related articles for article (PubMed ID: 35195008)
1. Peptides for Vaccine Development.
Hamley IW
ACS Appl Bio Mater; 2022 Mar; 5(3):905-944. PubMed ID: 35195008
[TBL] [Abstract][Full Text] [Related]
2. The Peptide Vaccine of the Future.
Nelde A; Rammensee HG; Walz JS
Mol Cell Proteomics; 2021; 20():100022. PubMed ID: 33583769
[TBL] [Abstract][Full Text] [Related]
3. Design of Peptide-Based Nanovaccines Targeting Leading Antigens From Gynecological Cancers to Induce HLA-A2.1 Restricted CD8
Xiang SD; Wilson KL; Goubier A; Heyerick A; Plebanski M
Front Immunol; 2018; 9():2968. PubMed ID: 30631324
[TBL] [Abstract][Full Text] [Related]
4. Peptide-based therapeutic cancer vaccine: Current trends in clinical application.
Liu W; Tang H; Li L; Wang X; Yu Z; Li J
Cell Prolif; 2021 May; 54(5):e13025. PubMed ID: 33754407
[TBL] [Abstract][Full Text] [Related]
5. Self-adjuvanting lipoimmunogens for therapeutic HPV vaccine development: potential clinical impact.
Shen KY; Chang LS; Leng CH; Liu SJ
Expert Rev Vaccines; 2015 Mar; 14(3):383-94. PubMed ID: 25455657
[TBL] [Abstract][Full Text] [Related]
6. The influence of component structural arrangement on peptide vaccine immunogenicity.
Alharbi N; Skwarczynski M; Toth I
Biotechnol Adv; 2022 Nov; 60():108029. PubMed ID: 36028180
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity in humans of a transdermal multipeptide melanoma vaccine administered with or without a TLR7 agonist.
Meneveau MO; Petroni GR; Salerno EP; Lynch KT; Smolkin M; Woodson E; Chianese-Bullock KA; Olson WC; Deacon D; Patterson JW; Grosh WW; Slingluff CL
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34035112
[TBL] [Abstract][Full Text] [Related]
8. Optimization of Peptide Vaccines to Induce Robust Antitumor CD4 T-cell Responses.
Kumai T; Lee S; Cho HI; Sultan H; Kobayashi H; Harabuchi Y; Celis E
Cancer Immunol Res; 2017 Jan; 5(1):72-83. PubMed ID: 27941004
[TBL] [Abstract][Full Text] [Related]
9. An In vivo study: Adjuvant activity of poly-n-vinyl-2-pyrrolidone-co-acrylic acid on immune responses against Melanoma synthetic peptide.
Kızılbey K; Mansuroğlu B; Derman S; Mustafaeva Akdeste Z
Bioengineered; 2018 Jan; 9(1):134-143. PubMed ID: 28910565
[TBL] [Abstract][Full Text] [Related]
10. MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma.
Chianese-Bullock KA; Pressley J; Garbee C; Hibbitts S; Murphy C; Yamshchikov G; Petroni GR; Bissonette EA; Neese PY; Grosh WW; Merrill P; Fink R; Woodson EM; Wiernasz CJ; Patterson JW; Slingluff CL
J Immunol; 2005 Mar; 174(5):3080-6. PubMed ID: 15728523
[TBL] [Abstract][Full Text] [Related]
11. Induction of adaptive immune response by self-aggregating peptides.
Zepeda-Cervantes J; Vaca L
Expert Rev Vaccines; 2018 Aug; 17(8):723-738. PubMed ID: 30074424
[TBL] [Abstract][Full Text] [Related]
12. Precisely Shaped Self-Adjuvanting Peptide Vaccines with Enhanced Immune Responses for HPV-Associated Cancer Therapy.
Song Y; Su Q; Song H; Shi X; Li M; Song N; Lou S; Wang W; Yu Z
ACS Appl Mater Interfaces; 2021 Oct; 13(42):49737-49753. PubMed ID: 34648269
[TBL] [Abstract][Full Text] [Related]
13. Vaccine Adjuvant Incorporation Strategy Dictates Peptide Amphiphile Micelle Immunostimulatory Capacity.
Zhang R; Kramer JS; Smith JD; Allen BN; Leeper CN; Li X; Morton LD; Gallazzi F; Ulery BD
AAPS J; 2018 Jun; 20(4):73. PubMed ID: 29858738
[TBL] [Abstract][Full Text] [Related]
14. Combination vaccine based on citrullinated vimentin and enolase peptides induces potent CD4-mediated anti-tumor responses.
Brentville VA; Metheringham RL; Daniels I; Atabani S; Symonds P; Cook KW; Vankemmelbeke M; Choudhury R; Vaghela P; Gijon M; Meiners G; Krebber WJ; Melief CJM; Durrant LG
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32561639
[TBL] [Abstract][Full Text] [Related]
15. Protein and Peptide Biomaterials for Engineered Subunit Vaccines and Immunotherapeutic Applications.
Tsoras AN; Champion JA
Annu Rev Chem Biomol Eng; 2019 Jun; 10():337-359. PubMed ID: 31173518
[TBL] [Abstract][Full Text] [Related]
16. [Subunit vaccines--antigens, carriers, conjugation methods and the role of adjuvants].
Jarząb A; Skowicki M; Witkowska D
Postepy Hig Med Dosw (Online); 2013 Nov; 67():1128-43. PubMed ID: 24379254
[TBL] [Abstract][Full Text] [Related]
17. Short Peptide Vaccine Induces CD4+ T Helper Cells in Patients with Different Solid Cancers.
Gross S; Lennerz V; Gallerani E; Mach N; Böhm S; Hess D; von Boehmer L; Knuth A; Ochsenbein A; Gnad-Vogt U; Forssmann U; Woelfel T; Kaempgen E
Cancer Immunol Res; 2016 Jan; 4(1):18-25. PubMed ID: 26563311
[TBL] [Abstract][Full Text] [Related]
18. Targeting Angiogenesis With Peptide Vaccines.
Rahat MA
Front Immunol; 2019; 10():1924. PubMed ID: 31440262
[TBL] [Abstract][Full Text] [Related]
19. Peptide Immunotherapy in Vaccine Development: From Epitope to Adjuvant.
Yang H; Kim DS
Adv Protein Chem Struct Biol; 2015; 99():1-14. PubMed ID: 26067814
[TBL] [Abstract][Full Text] [Related]
20. Peptide vaccines in breast cancer: The immunological basis for clinical response.
Peres Lde P; da Luz FA; Pultz Bdos A; Brígido PC; de Araújo RA; Goulart LR; Silva MJ
Biotechnol Adv; 2015 Dec; 33(8):1868-77. PubMed ID: 26523780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
